This study is looking at how well two treatment plans work for people with relapsed or refractory multiple myeloma. One treatment plan includes mezigdomide, bortezomib, and dexamethasone. The other plan includes pomalidomide, bortezomib, and dexamethasone. The goal is to see which plan is more effective and safe for patients who have already received 1 to 3 treatments before.
The trial ID is NCT05519085. This is a Phase 3 study, which means it is looking at how well the treatments work and how safe they are. The trial is FDA-regulated and aims to include about 810 participants.
Who can join
This study is open to adults aged 18 and older, both men and women, who have a diagnosis of multiple myeloma with measurable disease. Participants must have received 1 to 3 prior lines of therapy and achieved at least a minimal response to one treatment. Some people may not be eligible if they have certain prior treatments or progressions during their last therapies. The trial team will confirm who can join.
Condition
Relapsed or Refractory Multiple Myeloma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of two groups. One group will receive mezigdomide, bortezomib, and dexamethasone, while the other group will receive pomalidomide, bortezomib, and dexamethasone. Everyone will receive their assigned treatment on specific days throughout the study. There are no masked treatments, meaning everyone knows what they are receiving.
Where
This trial is enrolling at 56 locations. Recruiting sites are listed first.
Aurora, Colorado
Not Yet Recruiting
Ridgewood, New Jersey
Not Yet Recruiting
Shreveport, Louisiana
Not Yet Recruiting
Abilene, Texas
Active Not Recruiting
Albuquerque, New Mexico
Active Not Recruiting
Allentown, Pennsylvania
Completed
Ann Arbor, Michigan
Active Not Recruiting
Athens, Georgia
Active Not Recruiting
Study contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Directs the Lipper Myeloma Center, Dana-Farber. Treats multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.